References
- Amery W., Dony J. A clinical trial design avoiding undue placebo treatment. J. Clin. Pharmacol. 1975; 15: 674–6791. Amery W., Dony J. A clinical trial design avoiding undue placebo treatment. J. Clin. Pharmacol. 1975; 15: 674–679
- Chipman M., Kaul S., Lambie M. Efficacy of dantrolene sodium in the treatment of spasticity. Dis. Nerv. Sys. 1974; 35: 427–4312. Chipman M., Kaul S., Lambie M. Efficacy of dantrolene sodium in the treatment of spasticity. Dis. Nerv. Sys. 1974; 35: 427–431
- Chyatte S. B., Birdsong J. H., Bergman B. A. The effects of dantrolene sodium on spasticity and motor performance in hemiplegia. South. Med. J. 1971; 64: 180–1853. Chyatte S. B., Birdsong J. H., Bergman B. A. The effects of dantrolene sodium on spasticity and motor performance in hemiplegia. South. Med. J. 1971; 64: 180–185
- Chyatte S. B., Birdsong J. H., Roberson D. L. Dantrolene sodium in athetoid cerebral palsy. Arch. Phys. Med. Rehabil. 1973; 54: 365–3684. Chyatte S. B., Birdsong J. H., Roberson D. L. Dantrolene sodium in athetoid cerebral palsy. Arch. Phys. Med. Rehabil. 1973; 54: 365–368
- Dykes M. H. M. Evaluation of a muscle relaxant: dantrolene sodium (Dantrium). J.A.M.A. 1975; 231: 862–8645. Dykes M. H. M. Evaluation of a muscle relaxant: dantrolene sodium (Dantrium). J.A.M.A. 1975; 231: 862–864
- Gelenberg A. J., Poskanzer D. C. The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology 1973; 23: 1313–13156. Gelenberg A. J., Poskanzer D. C. The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology 1973; 23: 1313–1315
- Hollander M., Wolfe D. S. “Nonparametric Statistical Methods”. Wiley, New York 1973; 138–1467. Hollander M., Wolfe D. S. “Nonparametric Statistical Methods”. Wiley, New York 1973; 138–146
- Haslam R. H. A., Walcher J. R., Lietman P. S., Kallman C. H., Mellits E. D. Dantrolene sodium in children with spasticity. Arch. Phys. Med. Rehabil. 1974; 55: 384–3888. Haslam R. H. A., Walcher J. R., Lietman P. S., Kallman C. H., Mellits E. D. Dantrolene sodium in children with spasticity. Arch. Phys. Med. Rehabil. 1974; 55: 384–388
- Mayer N., Mecomber S. A., Herman R. Treatment of spasticity with dantrolene sodium. Am. J. Phys. Med. 1973; 52: 18–299. Mayer N., Mecomber S. A., Herman R. Treatment of spasticity with dantrolene sodium. Am. J. Phys. Med. 1973; 52: 18–29
- Pinder R. M., Brogden R. N., Speight T. M., Avery G. S. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977; 13: 3–2310. Pinder R. M., Brogden R. N., Speight T. M., Avery G. S. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977; 13: 3–23
- Schmidt R. T., Lee R. H., Spehlmann R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J. Neurol. Neurosurg. Psychiatry 1976; 39: 350–35611. Schmidt R. T., Lee R. H., Spehlmann R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J. Neurol. Neurosurg. Psychiatry 1976; 39: 350–356
- Utili R., Boitnott J. K., Zimmerman H. J. Dantrolene-associated hepatic injury incidence and character. Gastroenterology 1977; 72: 610–61612. Utili R., Boitnott J. K., Zimmerman H. J. Dantrolene-associated hepatic injury incidence and character. Gastroenterology 1977; 72: 610–616